Bruce Cameron Conway

U.S. SECURITIES AND EXCHANGE COMMISSION

Litigation Release No. 26568 / June 16, 2026

Securities and Exchange Commission v. Bruce Cameron Conway, No. 3:35-cv-2101 (N.D. Tex. filed Aug. 7, 2025)

SEC Settles Litigation with Texas Resident Charged with Insider Trading

On June 15, the Securities and Exchange Commission filed a consent and proposed final judgment as to defendant Bruce Cameron Conway, whom the SEC previously charged with insider trading.

The SEC’s complaint, filed on August 7, 2025 in the U.S. District Court for the Northern District of Texas, alleged that in July 2020, after agreeing to confidentiality terms, Conway obtained material nonpublic information regarding a privately-held biotechnology firm in which Conway was invested and its plan to merge with Cancer Genetics. The complaint further alleged Conway purchased Cancer Genetics shares on the basis of that information in fifteen accounts belonging to him, his family members, and family-owned trusts. As alleged, on August 24, 2020, the merger was publicly announced, the price of Cancer Genetics stock rose by 215 percent from the previous day’s closing price, and Conway began selling his Cancer Genetics shares.

Without admitting the allegations in the SEC’s complaint, Conway consented to the entry of a final judgment, subject to court approval, in which he agreed to be permanently enjoined from violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder; and to pay disgorgement of $60,201.95, prejudgment interest of $19,461.39, and a civil penalty of $160,936.22.

The SEC’s litigation was conducted by John Dwyer and Jodanna Haskins, under the supervision of Gregory A. Kasper. The SEC’s investigation was conducted by John Dwyer and supervised by Kimberly Frederick and Nicholas Heinke, all of the SEC’s Denver Regional Office. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.